• If you are wondering whether Vertex Pharmaceuticals at around US$425 per share offers good value or is already pricing in too much optimism, this article breaks down what the current stock price may be implying.
• The stock is around US$425 after a 0.6% slip over the last week, a 1.6% decline over the last month and a 6.0% decline year to date. The 1 year return sits at 1.1%, the 3 year at 21.3% and the 5 year at 98.3%.
• Recent attention around Vertex has focused on its product pipeline and regulatory progress, which often shapes how investors think about long term cash generation and risk. This context helps explain why the stock can move even when there is no single headline driving the price on a given day.
• Vertex currently scores 5 out of 6 on Simply Wall St's valuation checks. The next sections will look at how methods like DCF, multiples and other tools line up with that score, before finishing with a way to tie these numbers back to the broader story of the stock.

Approach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the company might generate in the future and discounting those cash flows back to today.

For Vertex Pharmaceuticals, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections. The latest twelve month free cash flow is about $3.76b. Analyst estimates run out after several years, so projections from 2026 to 2030 and beyond are extended using Simply Wall St assumptions.

Within this framework, forecast free cash flow reaches about $7.53b in 2030, with intermediate years between 2026 and 2035 ranging from roughly $4.86b to just over $10.01b before discounting. All of these cash flows are converted to today’s dollars using a discount rate, then summed to arrive at an estimated intrinsic value per share of around $764.82.

Compared with the recent share price of about $425, this implies the stock is 44.4% undervalued according to this DCF model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 44.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Vertex Pharmaceuticals Price vs Earnings

For a profitable company, the P/E ratio is a useful way to connect what you pay for the stock with the earnings it currently generates. Higher expected growth and lower perceived risk usually support a higher “normal” P/E, while slower growth or higher risk tend to justify a lower one.

Vertex Pharmaceuticals currently trades on a P/E of about 24.9x. That sits above the broader Biotechs industry average of around 17.8x, but below the peer group average of roughly 39.6x. Simply Wall St also calculates a “Fair Ratio” of 25.9x, which is the P/E that might be expected for this company given factors such as its earnings profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple comparison with industry or peers, because it adjusts for differences in growth, risk and business quality rather than assuming all companies should trade on the same multiple. With Vertex’s current P/E of 24.9x sitting a little below the Fair Ratio of 25.9x, this approach suggests the stock may be slightly undervalued on earnings.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you turn your view of Vertex Pharmaceuticals into a clear story that links what you think about its cystic fibrosis and nephrology pipeline to specific forecasts for revenue, earnings, margins and then to a Fair Value that you can compare with today’s price.

Within the Community page you can see different Narratives side by side, such as a cautious view that anchors on a Fair Value around US$330 and assumes tighter pricing, higher R&D needs and slower growth, alongside an optimistic view that points to a Fair Value near US$641 based on stronger uptake for therapies like ALYFTREK, CASGEVY, JOURNAVX and povetacicept. Each Narrative updates automatically as new earnings, trial results or regulatory news comes through so you always see how fresh information might change whether the stock looks expensive or cheap to you.

For Vertex Pharmaceuticals, however, we will make it really easy for you with previews of two leading Vertex Pharmaceuticals Narratives:

Fair value in this bullish Narrative: US$641.00

Implied discount to that fair value at around US$425: about 33.7%.

Revenue growth assumption: 15.70% a year.

• Assumes ALYFTREK, JOURNAVX, CASGEVY and the renal franchise keep CF at the core while broadening revenue into kidney disease, pain and cell or gene therapies.
• Expects margins to rise as higher royalty burdens ease, scale benefits flow through and cash generation supports continued R&D and selective deals.
• Sees the stock as attractive if you agree that earnings can reach about US$8.6b by 2029 on a 22.4x P/E multiple, using a 7.1% discount rate.

Fair value in this cautious Narrative: US$409.44

Implied premium to that fair value at around US$425: about 3.8%.

Revenue growth assumption: 6.81% a year.

• Highlights pressure from drug pricing reforms, high treatment costs and concentrated exposure to rare genetic diseases as potential headwinds for long term margins.
• Flags execution risk and high ongoing R&D needs, especially if newer therapies like CASGEVY or povetacicept face access limits or tougher competition.
• Views the stock as closer to fully priced if earnings slide to about US$3.4b by 2029 and the market still assigns a higher 36.7x P/E multiple, on a 7.15% discount rate.

With these two Narratives side by side, you can decide which assumptions feel closer to your own expectations and then adjust the inputs rather than starting your Vertex Pharmaceuticals view from scratch.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vertex Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.